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In 2017, 11.4 million US citizens misused prescription opioids, re ulting in 46 overdose-
deaths daily and a $78.5 billion burden o  the economy. Dentists are one of the most frequent 
prescribers of opioids and there is concern that dental prescribing is contributing to the opioid 
crisis.  
Methods. 
A recent study showed 22.3% of US dental prescriptions were for opi ids compared to 0.6% 
in England, where nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen 
accounted for most analgesic prescriptions. This observation pr mpted a review of 
international analgesic prescribing habits and of the advantages and disadvantages of opioids 
and NSAIDs for treating dental pain. 
Results. 
US opioid prescribing far exceeded that in other countries where NSAIDs accounted for the 
vast majority of dental analgesic prescribing. Furthermore, recent reviews confirm NSAIDs, 
and NSAID-acetaminophen combinations are as or more effective than opioids for 
controlling dental pain and cause significantly fewer side-eff cts. 
Conclusions. 
In light of the potential for misuse, and evidence that NSAIDs are as effective as opioids and 
have fewer side effects, there is clear patient benefit i  avoiding opioids for the prevention or 
management of dental pain. 
Practical Implications. 
A growing preponderance of evidence shows that opioids are not needed for routine dental 
care. This article provides an overview of the evidence ad outlines possible pain 
management models to minimize opioid use in dentistry. The purpose is to stimulate debate 
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on this important topic and encourage the development of definitive guidance by professional 
bodies, health providers, and state and federal agencies. 
Keywords: 
Odontogenic Pain, Post-operative analgesia, Dental, Opioid, NSAID, Acetaminophen, 
Analgesic, Opioid Crisis, Guidelines. 
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The U.S. Department of Health and Human Services declared the opioid crisis a public health 
emergency in October 2017.1 The crisis has its roots in the 1990s when pharmaceutical 
companies convinced the medical community that patients would not become addicted to 
newer opioid pain relievers, such as oxycodone. The initial perceived safety of newer opioids, 
coupled with quality metrics emphasizing aggressive pain control, fueled a 4-fold rise in opioid 
sales between 1999 and 2010.2 Increased prescribing of opioids led to widespread misuse of 
both prescription and non-prescription opioids before it became clear that these medications 
could indeed be highly addictive. 
The Centers for Disease Control and Prevention (CDC) quantifies the devastation caused by 
the massive increase in opioid prescriptions in the U.S. The most recent data from 2017 
estimates that 11.4 million people misuse prescription opioids and 46 die each day from 
overdoses involving these drugs.3, 4 This number accounts for nearly a third of the more than
130 deaths a day from all types of opioid related overdose (illicit and prescription).5 The 
economic burden of prescription opioid misuse in the U.S. was estimated to be $78.5 billion 
for calendar year 2013.6 Opioid misuse is associated with an overall decrease in U.S. life 
expectancy,7, 8 with prescription opioid related overdose deaths five times higher in 2017 than 
in 1999.3  
The prescription opioid crisis is very much focused on the U.S., which consumes 80% of the 
global opioid supply despite representing only 5% of the world’s population.9, 10 Globally, 
prescription opioids are among the most commonly misused and abused medicines. In the U.S., 
Canada, and to a lesser extent Australia and New Zealand, illicit use of prescription opioids 





Dentists account for 8.6% of all opioid prescribing. This is jut behind pain medicine 
physicians (8.9%) but significantly less than family (20.5%) and internal medicine (15.7%).13-
16 While overall opioid prescribing has decreased by 27.5% nationally between 2012 and 
2017,13, 17, 18 in part due to the introduction of Prescription Drug Monitoring Programs 
(PDMP),19 dental prescribing rates have fallen by only 2.2% over the same period.13, 17, 20 
Perhaps most worrysome, dentists are the leading source of opioids for children and 
adolescents aged 10 to 19.16 In 2009, dentists accounted for 31% of opioid prescriptions in this 
age group and, between 2010 and 2015, the largest increase in dental opioid prescriptions was 
among 11 to 18-year-olds.16 Recent evidence suggests that dental exposure to opioids in pioid-
naïve adolescents and young adults is associated with higher rates of opioid use between 3 
months and a year later compared to controls. Even more troubling, adolescents and young 
adults prescribed opioids by dentists were more likely to have subsequent diagnoses associated 
with opioid abuse or overdose.21  
Studies have also shown that dentists prescribe opioids in greater quantities, at higher strength, 
and for longer periods than are necessary to control dental pain.14, 22-25 In part, this may be 
because dentists tend to overestimate the pain associated with dental procedures.26 In addition, 
dentists often prescribe opioid pain relief “just in case” or “to be taken as needed”.14 As a result, 
more than half of opioids prescribed following tooth extraction remain unused.27 This could 
release large numbers of opioid pills to be diverted to other purposes27 with the potential for 
opioid abuse and dependence.21, 28, 29  
The main source of prescription drugs diverted to non-medical use are family members or 
friends who give or share their prescription medication o help a friend or family member in 
physical distress or pain14. Such use is illegal and a significant factor in facilitating opioid 
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abuse.30-32 In other cases, those already addicted or those involved in the illegal supply of 
opioids, may ‘shop around’ for sources of prescription opioids and falsify or exaggerate their 
pain in order to access opioids. Dentists have been identif ed as among those prescribers that 
substance abusers most commonly target when ‘doctor shopping’ to obtain multiple 
prescriptions of controlled substances, including opioids.14, 18, 25 
The opioid most frequently prescribed by dentists is hydrocod ne followed by codeine, 
oxycodone, and tramadol respectively.25 Hydrocodone is approximately equivalent to 
morphine in potency, while oxycodone is 1.5 times more powerful than morphine. In 
comparison, tramadol and codeine are approximately 1/10th the potency of morphine.33 
Unsurprisingly, hydrocodone and oxycodone are among the drugs most commonly associated 
with drug dependency and overdose deaths.34 Higher-potency and longer-acting opioids, 
agents at high risk for abuse and diversion, are also prescrib d by dentists.25 
How Does U.S. Dentistry Compare? 
A study recently published in JAMA Network Open,25 compared opioid prescribing by dentists 
in the United States and England. In the U.S. 22.3% of all dental prescriptions were for opioids 
compared to 0.6% of English dental prescriptions. At the patient level, this equated to 35.4 
prescriptions /1000 of the U.S. population (95%CI: 25.2-48.7) compared with 0.5/1000 of the 
English population (95%CI: 0.03-3.7). At the provider level, thisequated to 58.2 prescriptions 
per U.S. dental provider (95%CI: 44.9-75.0) compared with 1.2 prescriptions per English 
dental provider (95%CI: 0.2-5.6). Furthermore, the only opioid prescribed by dentists in 
England was di-hydrocodeine a semi-synthetic opioid with about 1/5th the potency of 
morphine.33 The vast majority of analgesic prescriptions by dentists in England were for non-
steroidal anti-inflammatory drugs (NSAIDs) or paracetamol (acetaminophen) and this pattern 
of prescribing is similar throughout the United Kingdom (U.K.). 
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These differences in opioid prescribing are huge and exist despite similar patterns of dental 
office visits by children and adults, no difference in oral health quality indicators, including 
untreated dental caries and edentulousness, and no evidence of significant differences in the 
patterns of dental disease or treatment between the two countries nor any evidence that dental 
patients suffer more pain in the UK as a result of these diff rences.25, 35-38 Although there are 
greater educational and income related health inequalities in the U.S., the overall oral health of 
U.S. and U.K. citizens is very similar.25, 35-38 These patterns of dental analgesic prescribing, 
however, are not unique to the U.K. and are replicated in many countries outside of North 
America. Numerous studies show no or very low opioid prescribing y dentists in much of 
Europe,25, 39-41 Asia42-44 and Africa.45 As is the case in the U.K., ibuprofen and other NSAIDs 
are by far the most frequently prescribed analgesics in these countries. Although there is 
significant opioid prescribing in Australia, it is almost entirely confined to prescribing of the 
combined paracetamol (acetaminophen) and codeine 30mg preparation.46  
The Roots of the Problem 
Prior to the 1990’s opioid use was largely restricted to cancer pain relief, terminal care and 
very short-term management of severe traumatic injuries or visceral pain. Most clinicians were 
concerned about the addiction risk and therefore very reluctant to prescribe opioids for chronic 
or non-cancer-related pain. 
In the late 1990’s studies focused on patient quality of life revealed that a third of the U.S. 
population were affected by chronic pain. In response, organizations like the Joint Commission 
pushed for increasing attention to pain assessment and treatment, referring to pain as the ‘fifth 
vital sign’.47 The concept that all patients should be screened for pain led to treatment of pain 
being raised to a ‘patients rights’ issue.47 During this time, reports appeared in the medical 
literature claiming that opioids were not addictive even when used for chronic non-cancer 
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pain.47-49 These findings opened the window for pharmaceutical companies to expand from the 
relatively small cancer pain and traumatic injury markets into the much larger chronic pain 
market. Some opioid manufacturers used seductive high-pressure ma keting and invited 
clinicians to all expenses paid, pain-management conferences. Th  purported lack of addictive 
potential was heavily promoted, with sales representatives falsely reporting to clinicians that 
the addiction potential was “less than one percent.”49 Even the initial FDA approval for 
OxyContin in 1996 stated that addiction was “very rare.” Clinicians also began prescribing 
opioids for acute pain. Furthermore, the idea that pain management was a patient right, led to 
a culture where patients expected to be able to demand opioids for pain relief and clinicians, 
including dentists, felt it was in their patient’s best interests to prescribe them. This perfect 
storm of conditions made opioid prescribing for pain the norm in the U.S. but the same 
conditions didn’t exist to the same degree in other countries. 
Why didn’t these problems evolve elsewhere? 
There are several reasons why these conditions were not replicated outside the U.S. For 
example, many other countries have strict regulations governing the use of advertising, 
entertainment, and other inducements to persuade clinicians to prescribe particular drugs or 
make unevidenced claims about them. Many countries also have n tional guidelines on 
managing dental pain and formularies or regulations that limi the prescribing of drugs by 
dentists. Additionally, healthcare policy stakeholders in other countries also did not engage in 
the misconstrued effort to aggressively combat chronic pain with oral prescription opioids. 
Evidence for the Efficacy of Different Dental Analgesics 
Analgesic prescribing in dentistry occurs largely in two situations (i) to provide relief from 
odontogenic pain e.g. pulpitis, apical infection, localised osteitis or pericoronitis, or (ii) for pain 
control following invasive dental procedures e.g. dental extractions. 
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Odontogenic pain is mainly inflammatory in origin, caused by the interaction of microbial 
pathogens with host tissues to cause an acute inflammatory response. The most appropriate 
response is to drain any abscesses, treat infection that may have spread, reduce inflammation, 
and achieve definitive cause control using restorative, endodontic, or oral surgical procedures. 
When analgesia is required, a medication with anti-inflammatory properties is the most logical 
choice, as it will have the dual effect of reducing inflammation while relieving pain. There are 
few studies specifically looking at the use of different analgesics for relieving acute 
odontogenic pain. However, a recent study showed that one third of opioid prescriptions to 
Medicaid beneficiaries were issued in association withnon-invasive dental visits and the mean 
duration of opioid prescription was significantly higher than for invasive procedure related 
visits. This is concerning, since it suggests the possibility that patients are being offered opioids 
instead of definitive treatment of their odontogenic pain.50 Similarly, non-traumatic dental pain 
accounted for 2.18 million emergency department (ED) visits in 2012, nearly 2% of the total, 
and 50.3% of them received an opioid prescription compared to jus  14.8% of all other ED 
patients. Indeed, patients who presented to the ED with non-traumatic dental pain were twice 
as likely to receive an opioid than a non-opioid or no pain medication.51 Furthermore, most 
prescriptions were to ‘keep the patient going’ until they could receive definitive dental 
treatment, a situation commonly associated with higher dose and longer duration of 
prescription and with opioid abuse and diversion. 
Management of pain relief in association with invasive dental procedures has been much more 
extensively studied, largely because of the ease of use and predictability of the third molar 
extraction model for clinical trials. Recently, Moore et al performed an overview of systematic 
reviews of analgesic medications used in the management of acute dental pain at the request of 
the American Dental Association (ADA) Council on Dental Practice.52 This review concluded 
that NSAIDs, either alone or in combination with acetaminophen, were equal or superior to 
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opioid-containing medications for relief of post-operative dental pain. Furthermore, opioid 
medication and opioid medication combinations were associated with higher rates of acute 
adverse events.52 Another systematic review of the management of endodontic procedure 
related pain, also concluded that “NSAIDs should be considered as the drugs of choice to 
alleviate or minimize pain of endodontic origin.” In settings where NSAIDs alone are 
ineffective, the authors recommended using “an NSAID with acetaminophen or a centrally 
acting drug.”53 
How Can We Reduce Dentistry’s Dependency on Opioid Analgesics? 
Given this evidence, action is required to reduce opioid prescribing in dentistry. How then can 
this be achieved? Widely accepted pain management guidelines are es ential. The ADA’s 2016 
Statement on the Use of Opioids in the Treatment of Dental Pain provides the following 
anodyne recommendation: “Dentists should consider nonsteroidal anti-inflammatory 
analgesics as the first-line therapy for acute pain management”.54 Similarly, the CDC 
recommendations focus on the management of long-term pain with opioids and say little on 
their use for acute pain management.55 
The National Academy of Medicine (NAM) recommends that dentists use non-opioid 
analgesics for post-procedural pain and counsel patients about the risks and benefits of opioids, 
evaluate the risk of opioid abuse and utilize PDMPs prior to prescribing opioids.56 A recent 
survey, however, found that nearly half of dentists reported having never accessed a PDMP, 
most often because of lack of awareness. Mandated use was associated with the highest access 
of PDMP and most dentists found them very helpful.57  
Achieving the goal of reducing opioid prescribing in dentistry would also be aided by the use 
of formularies or regulations that limit the prescribing of drugs by dentists as occurs in 
countries such as the UK. Restrictions on the use of some drugs by U.S. dentists may be an 
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unpopular solution, but dentists in the UK have not felt limited in their professional capacity 
by the Dental Practitioners Formulary (which is part of he British National Formulary) that 
defines the nature, dose and duration of drugs that can be prescribed by dentists. Indeed, such 
restriction, along with national prescribing guidelines, makes discussions with patients who 
expect or demand opioids much easier, since both patients and dentists know the limits of what 
constitutes professional and legal prescribing. Such changes may require action by state 
regulators and state boards and/or prescription benefit insurers and organisations. The advice 
on short-term use of opioids in the recent CDC Guidelines suggest it would not be unreasonable 
to limit opioid prescribing by dentists to three-day’s supply of immediate-release opioids and 
limit the dose to a maximum of 50 morphine milligram equivalents (MME) per day.55 This is 
supported by a recent study that found that the median duration of pioid supply by dentists 
was 3 days and the median daily dose was 33.3 MME, suggesting that many dental opioid 
prescriptions are within these limits. However, in the same study, the mean number of days 
supply was 4.82 (SD +/- 5.92) and the mean daily dose 43.05 MME (SD +/- 68.71) suggesting 
that a significant number of dental opioid prescriptions also exceed these limits.58 Other unsafe 
opioid prescribing practices that have been identified, and could be avoided by the use of 
PDMP, include repeat and overlapping opioid prescriptions.24, 58 Recently published data 
suggests that some dentists also issue prescriptions for agents at high potential for misuse (e.g, 
oxycodone, long-acting opioids) that have no place in the management of dental pain.25  
Managing Odontogenic and Post-Operative Pain in General Dental Practice 
How then should dental pain be managed? To address this, we have drawn on the findings of 
the reviews cited above,52, 53 the advice of the ADA,54, 59 CDC,55 NAM recommendations,56 
and current UK guidelines.60, 61 
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In the case of odontogenic pain, most authorities agree that it is essential that dentists prioritise 
identifying and treating the cause of the pain. Where an abscess exists, drainage should be 
obtained by endodontic treatment, surgical incision and drainage, or extraction of the tooth 
depending on what is most appropriate. Other causes of dental pain should be treated with 
appropriate restorative or other dental care. Where there is spreading infection or pyrexia, 
appropriate antibiotic treatment should be started, and, if appropriate, referral to specialist oral 
surgical care considered.60  
Where pain is mild to moderate, recent studies suggest management with ibuprofen 400mg 
four times daily, for 5 days (preferably after food) provides effective analgesia.52, 53, 60, 61 For 
moderate to severe pain, recent studies suggest ibuprofen 400mg plus acetaminophen 1000mg 
four times daily for 5 days (preferably after food) provide as effective, if not more effective 
pain relief than opioids.52, 53, 60, 61 These doses are for adults and should be amended as 
appropriate in children and adolescents. The same analgesic strategies are also recommended 
for short term pain relief, pending definitive treatment of the cause, which should not be 
delayed more than 24-72 hours.60, 61 They are also recommended for post-operative pain 
management e.g. following third molar surgery,52, 53 when it is recommended that analgesia is 
commenced before the local anaesthesia wears off in order to optimise pain relief.  
NSAIDs such as ibuprofen are contraindicated in those with a history active or previous peptic 
ulcer or in those with a history of hypersensitivity to aspirin or other NSAIDs, including those 
in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by 
NSAIDs. Caution should also be exercised about the use of NSAIDs in the elderly, pregnant 
women, nursing mother, those taking oral anticoagulants suchas warfarin, those with 
coagulation defects, inherited bleeding disorders or renal impair ent.60, 61 In such situations, it 
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is recommended that acetaminophen 1000mg, is prescribed four times daily for 5 days, or 
another alternative to NSAIDs is used. 52, 53, 60, 61 
In those with previous or active peptic ulcers, where acetaminophen alone will provide 
insufficient analgesia, it has been recommended that ibuprofen or diclofenac could be 
prescribed in conjunction with a proton pump inhibitor e.g. lansoprazole 15mg or omeprazole 
20mg once daily for the duration of the NSAID treatment.61 
Patients should be advised not to exceed the prescribed dose and that the aim of the analgesia 
is to make them as comfortable as possible, but some discomfort is normal and still may 
occur.52 Following an operative procedure, as the patient’s discomfort improves, they should 
feel free to reduce and stop their medication as they feel able. 
Current evidence makes a compelling case in favour of the use of NSAIDs with or without 
acetaminophen for all types of dental pain except where NSAID are contraindicated and should 
be used as first-line therapy for acute pain management.52-54, 56, 59 And this information should 
be discussed with any patient requesting an opioid for dental pain relief.56  However, when an 
opioid is considered necessary, it is recommended that patients are properly evaluated for 
suitability, prior opioid use and the potential for misuse or diversion of supplies.56, 59 To 
facilitate this, dentists should consult the PDMP each time an opioid is prescribed.57, 59 When 
opioids are used for acute pain, clinicians should prescribe the lowest effective dose of 
immediate-release opioids for the shortest anticipated duration.55 The CDC recommends 
writing opioids prescriptions for 3 days duration or less.55 If pain extends beyond this, NSAIDs 
or acetaminophen should be sufficient to manage any residual discomfort. The lowest effective 
dose should not exceed a maximum of 50 morphine milligram equivalents (MME)/day 
(morphine MME = 1, hydrocodone MME = 1, oxycodone MME = 1.5, codeine MME = 0.15. 
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Therefore, a maximum of 50mg hydrocodone/day, 30mg of oxycodone/day or 75mg of 
codeine/day).55  
Conclusions: 
In light of evidence showing that NSAIDs are at least as effective as opioids in the management 
of odontogenic and dental post-operative pain, and cause significantly fewer side effects, there 
is clear patient benefit in moving away from opioids in the management of these conditions. 
When this is put alongside the opioid crisis, the case for taking action now to end U.S. 
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